SCHEDULE: State Street Discloses 6.4% Stake in Janux Therapeutics

State Street Corporation has reported a 6.4% beneficial ownership stake in Janux Therapeutics Inc. common stock as of December 31, 2025.

Summary

• State Street Corporation, a Massachusetts-based entity, filed a Schedule 13G regarding its ownership in Janux Therapeutics Inc.
• As of December 31, 2025, State Street Corporation beneficially owned 3,853,951 shares of Janux Therapeutics Inc. common stock.
• This represents 6.4% of the total outstanding shares of Janux Therapeutics Inc.
• State Street Corporation holds shared voting power over 3,749,880 shares and shared dispositive power over 3,853,951 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-slightly positive disclosure, as it indicates a significant institutional investment in Janux Therapeutics Inc. without any negative implications, but it does not provide operational or financial performance data.

Positives

• A major financial institution, State Street Corporation, holds a significant stake (6.4%) in Janux Therapeutics, potentially indicating institutional confidence.
• The acquisition of shares is stated to be in the ordinary course of business, suggesting a passive investment rather than an activist stance.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding Janux Therapeutics Inc.'s future outlook, as it is solely a disclosure of beneficial ownership by State Street Corporation.

Management Comments

• The filing includes a certification from State Street Corporation's Senior Vice President, Chief Accounting Officer, Elizabeth Schaefer, stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Janux Therapeutics Inc.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes, which can sometimes signal institutional confidence in a company within the biotechnology sector. While not an endorsement, a substantial holding by a major asset manager like State Street Corporation is a common occurrence for publicly traded companies.

Comparison to Industry Standards

• This filing is a standard disclosure of a significant passive ownership stake by an institutional investor.
• It does not provide operational or financial results for Janux Therapeutics Inc. that would allow for a direct comparison to industry benchmarks or specific comparable companies/projects.
• The 6.4% stake is a notable institutional position.

Stakeholder Impact

• Shareholders: Increased transparency regarding institutional ownership.
• Investors: Provides insight into a major financial institution's position in Janux Therapeutics Inc.

Key Dates

Recommendation

This Schedule 13G filing merely discloses a passive ownership stake by State Street Corporation and does not contain information about Janux Therapeutics Inc.'s operational performance, financial health, or strategic direction that would warrant a 'buy' or 'sell' recommendation. It confirms institutional interest but provides no new fundamental data to alter an existing investment thesis. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Janux Therapeutics, State Street Corporation, Schedule 13G, Common Stock, Institutional Ownership, Biotechnology, Pharmaceuticals, Investment, SEC Filing